Navigation Links
Oncolytics Biotech Inc. Announces 2008 First Quarter Results
Date:4/30/2008

p> Therapeutics Inc. - - 2,156,685

Gain on sale of BCY

LifeSciences Inc. - - (299,403)

Cancellation of contingent

payment obligation settled

in common shares - - 150,000

Future income tax recovery - - (1,115,000)

-------------------------------------------------------------------------

- - 1,383,537

-------------------------------------------------------------------------

-------------------------------------------------------------------------

6. CAPITAL DISCLOSURES

The Company's objective when managing capital is to maintain adequate

cash resources to support planned activities which include the clinical

trial program, product manufacturing, administrative costs and

intellectual property expansion and protection. The Company includes

shareholders' equity, cash and short-term investments in the definition

of capital. The Company does not have any debt other than trade accounts

payable and has potential contingent obligations relating to the

completion of its research and development of REOLYSIN(R).

In managing capital, the Company estimates its future cash requirements

by preparing a budget and a multiyear plan annually for review and

approval by the Company's board of directors (the "Board"). The budget

establishes the approved activities for the upcoming year and estimates

the costs associated with these activities. The multiyear plan estimates

future activity along with the potential cash requirements and is based

on the Company's assessment of its current clinical trial progress along

with the expected results from the coming year's activity. Budget to

actual variances are prepar
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... , June 2, 2015 /CNW/ - Shell today celebrated ... in the premium category with an exhibit the size ... that included interactive demonstrations for media and the public, ... Shell V-Power NiTRO+ Premium Gasoline provides the best total ... engine performance: engine wear, gunk and corrosion. ...
(Date:6/2/2015)... SAN DIEGO and TORONTO ... APTO ; TSX: APS), a clinical-stage company developing ... today announced that the U.S. Food and Drug Administration ... APTO-253 for the treatment of acute myeloid leukemia (AML). ... the company,s lead product candidate in a Phase Ib ...
(Date:6/2/2015)... MIAMI (PRWEB) June 02, 2015 Global ... Latin America distributor for Bioquark, Inc.’s biologic products for the ... is the latest in Global Stem Cells Group’s ambitious expansion ... region’s growing demand for access to regenerative medicine and stem ... on the development of biologics that have the ability to ...
(Date:6/2/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/6wjpd6/bioburden_testing ) ... Market by Product , Test, Application & End User ... The bioburden testing market is expected to ... 2014, growing at a CAGR of 9.8% from 2014 ... microbial limit testing market is segmented into consumables and ...
Breaking Biology Technology:New Shell V-Power NiTRO+ Premium Gasoline Introduces Breakthrough Formulation for BEST TOTAL Engine Protection 2New Shell V-Power NiTRO+ Premium Gasoline Introduces Breakthrough Formulation for BEST TOTAL Engine Protection 3New Shell V-Power NiTRO+ Premium Gasoline Introduces Breakthrough Formulation for BEST TOTAL Engine Protection 4Aptose Biosciences Granted Orphan Drug Designation by the U.S. FDA for APTO-253 in Acute Myeloid Leukemia 2Aptose Biosciences Granted Orphan Drug Designation by the U.S. FDA for APTO-253 in Acute Myeloid Leukemia 3Aptose Biosciences Granted Orphan Drug Designation by the U.S. FDA for APTO-253 in Acute Myeloid Leukemia 4Adimarket Named Latin American Distributor for Bioquark Biologic Products for the Regeneration and Repair of Human Organs and Tissue with Stem Cells 2Adimarket Named Latin American Distributor for Bioquark Biologic Products for the Regeneration and Repair of Human Organs and Tissue with Stem Cells 3Bioburden Testing Market 2015 - Global Forecasts to 2019 2
... , , Alberta Centre ... health & medical seminar, , EDMONTON, Dec. 4 /PRNewswire/ ... how technologies like nanotechnology, biomaterials and microfluidics can play a ... help promote health and improve the quality, cost and outcomes ...
... , DALLAS, Dec. 3 ... Bulletin Board: ACCP), today provided an update on its European ... mucositis, a debilitating side effect of radiation treatment and chemotherapy. ... European countries, including the UK, Germany, Italy, Norway, Greece and ...
... , HOPKINTON, Mass., Dec. 3 Caliper Life Sciences, ... and services for drug discovery and life sciences research, today ... systems. Living Image software drives the more than 800 Caliper ... features advanced spectral unmixing tools to enhance fluorescent sensitivity and ...
Cached Biology Technology:Alberta companies delivering new products to the health & medical marketplace 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 3Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 4Caliper Life Sciences Launches Living Image(R) 4.0 Software 2
(Date:5/22/2015)... 22, 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... be ending its promotional pricing and making the Wocket generally ... Laurence Savin , Head of Marketing said, "We,ve extended the ... the end of May. To get your wocket at this ... open the store on June 1, you,ll receive a unique ...
(Date:5/21/2015)... The Sync Project™ , a global collaboration harnessing ... a collaborative partnership with Berklee,s Institute for Creative ... on original research, joint course development and an internship ... Sync Project and BerkleeICE are exploring the launch of ... academic year.  The course will focus ...
(Date:5/19/2015)... 2015 Fingerprint Cards (FPC) has received ... FPC1155 and FPC1035 from one if its module partners. Deliveries ... Q3 2015 and the sensors will be used by smartphone ... for 2015 hereby amount to 740 MSEK to date. In ... MSEK and a number of smaller orders not separately communicated ...
Breaking Biology News(10 mins):NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 2NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 3The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2
... early stages of cancer could one day result from new ... Universitys School of Medicine has just published a study on ... which can play a crucial part in the onset of ... by gradually becoming shorter they can tell cells when it ...
... beleaguered growers of popular cucurbit crops like cucumbers and ... (Lagenaria siceraria) appear to have resistance to Zucchini yellow ... includes pumpkins, squashes and other kinds of melons, including ... in other parts of world, and is a particular ...
... 2, 2007The Keck School of Medicine of the University of ... the Kenneth T. & Eileen L. Norris Foundation that will ... centers devoted to the study of epigenetics. The grant ... field that holds great promise in the treatment and prevention ...
Cached Biology News:Research points towards early cancer detection 2Battling virus disease of watermelon with bottlegourds 2$10 million gift to support cutting-edge epigenome center at USC 2$10 million gift to support cutting-edge epigenome center at USC 3
... TProfessional Thermocycler combines top performance with exquisite ... high speed and unparalleled temperature uniformity. The ... programming in a spreadsheet or alternatively in ... Lid opens on the push of a ...
... Ultra Agarose Spin Kit is an advanced system for ... purified DNA can be used directly for any downstream ... DNA is ready to use in 56 minutes ... used for TAE and TBE gels No specialised ...
... been designed for recovery of DNA from TAE and ... Ultra fast protocol: DNA is ready to use ... to resuspend Bead uniformity prevents shearing of high ... PCR) DNA is eluted into sterile water or ...
... agarose gels The SpinPrep Gel DNA Kit enables ... > 12,000 bp in size from agarose gels. The ... followed by adsorption of the DNA to a silica ... step, the purified DNA is eluted in low-salt buffer. ...
Biology Products: